Blog

Survivors gather for 20th anniversary of Oklahoma City bombing

By Heide Brandes OKLAHOMA CITY (Reuters) – When Priscilla Salyers attends Sunday’s anniversary ceremony for victims of the 1995 Oklahoma City bombing, she will be thinking how far she has come in fighting depression and survivor’s guilt. She and hundreds of other survivors will bow their heads at the 20th Remembrance Ceremony at the Oklahoma City National Memorial and Museum, marking the day a cargo truck with more than two

Life or death? Boston bomber's trial turns to sentencing

By Scott Malone BOSTON (Reuters) – Convicted Boston Marathon bomber Dzhokhar Tsarnaev is set to return to court on Tuesday for the next phase of his trial, when prosecutors will argue that he should be sentenced to death for his role in the deadly attack in 2013. In sharp contrast to the guilt phase of the trial, when lawyers for the ethnic Chechen defendant did not contest that their client

Fast-moving brush fire forces home evacuations near Los Angeles

(Reuters) – A fast-moving brush fire east of Los Angeles has forced the evacuation of more than 200 homes just hours after it started, fire department officials said on Sunday. The blaze, named the “Highway Fire,” was zero percent contained and had spread over 175 acres in Chino Hills, a suburb about 35 miles east of Los Angeles, according to a statement released by the City of Riverside Fire Department.

Paul, Graham clash on foreign-policy on U.S. campaign trail

By Andy Sullivan NASHUA, N.H. (Reuters) – Republican presidential hopefuls Rand Paul and Lindsey Graham took their debate over America’s role in the world from the U.S. Senate floor to the campaign trail on Saturday in an early sign that foreign policy is likely to be a flash point in the 2016 election. At a gathering of 18 potential and actual White House contenders, Paul accused fellow Republicans of being

Teva shares slide on generic Copaxone fears

By Steven Scheer and Tova Cohen TEL AVIV (Reuters) – Teva Pharmaceutical Industries shares slid five percent on Sunday after U.S. regulators approved a generic version of its top-selling multiple sclerosis drug and amid reports it was mulling a bid for rival Mylan. Teva’s Tel Aviv shares fell to 249.80 shekels ($64) late on Sunday, the first day of trading since both news hit the market on Thursday after Israel’s